Stipend and Dates

Up to $10,400 (multiple payments)

  Cohort 3
Admit Oct 28, 2021 Thurs
Discharge Oct 31, 2021 Sun
Day 7 Outpatient visit Nov 04 Thurs
Day 9 Outpatient visit Nov 06 Sat
Day 11 Outpatient visit Nov 08 Mon
Day 13 Outpatient visit Nov 10 Wed
Day 21 Outpatient visit Nov 18 Thurs
Day 28 Outpatient visit (payment 10 business days after visit) Nov 25 Thurs
Day 35 Outpatient visit Dec 02 Thurs
Day 49 Outpatient visit Dec 16 Thurs
Day 56 Outpatient visit Dec 23 Thurs
Day 70 Outpatient visit (payment 10 business days after visit) Jan 06, 2022 Thurs
Day 98 Outpatient visit Feb 03 Thurs
Day 112 End of study visit (payment 10 business days after visit) Feb 17 Thurs

 

Click here to make an appointment for AM 5480-0009

Or call 210-225-5437 for more information

 

Study Criteria

Healthy Males and Females

Age 18-45

BMI 18-30 (Weight must be between 110 and 198 pounds)

 

Study Information

Indication: The investigational drug is being developed to find out whether the investigational drug may help several autoimmune diseases

Route of Administration: SC (subcutaneous under the skin) either by an auto injector or prefilled syringe)

Washout from previous study: receiving or has received any investigational drug (or is currently using an investigational device) within the 30 days or 5 half-lives prior to 1st dose

Acceptable Birth Control for Females (if Childbearing):  Female subjects of childbearing potential must be willing to use 2 methods (1 primary highly effective and 1 secondary method) of birth control throughout the study and for an additional 5 months after the study drug injection or until your scheduled end of study visit (whichever is longer).

Primary (highly effective) methods of contraception include:

  • Hormonal injection (as prescribed)
  • Combined oral contraceptive pill or progestin/progestogen-only pill
  • Combined hormonal patch
  • Combined hormonal vaginal ring
  • Surgical method performed at least 3 months prior to the screening visit:
  • Bilateral tubal ligation with confirmation of surgical success
  • Regulatory approved method of hysteroscopic bilateral tubal occlusion with confirmation of occlusion of the fallopian tubes
  • Hormonal implant
  • Hormonal or non-hormonal intrauterine device/system
  • Vasectomized male partner

Secondary (barrier) methods of contraception include:

  • Male condom with spermicide
  • Female condom with spermicide
  • Over-the-counter (OTC) sponge with spermicide
  • Cervical cap with spermicide (as prescribed)
  • Diaphragm with spermicide (as prescribed).

 Acceptable Birth Control for Males:  Male subjects (even with a history of vasectomy) with partners of childbearing potential must use a male barrier method of contraception (for example, male condom with spermicide) throughout the study and for an additional 5 months after your study drug injection or until your scheduled end of study visit (whichever is longer).

 

Study Reminders

  • 8 hours fasting is required for lab work (only water is allowed)
  • If taking medications, bring them to your screening appointment
  • Bring a valid, non-expired photo ID with you when you attend your screening visit.  We accept a government issued identification card such as a driver's license, state issued ID card, military ID or passport.  You will be required to show this same photo ID at all study visits
  • Arrive 30 minutes before your appointment to complete paper work.
Reference
AM 5480-0009
Name
Healthy Adults
Details
NEW DATES! $200 Refer-A-Friend bonus available. Must weigh between 110 & 198 pounds.
Gender
Male or Female
Payment amount
Up to $10,400
Age
18 - 45
Smoking
Non-smokers